Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Thrombopoietin Receptor Agonists [MoA]

Known as: Thrombopoietin Receptor Agonists 
 
National Institutes of Health

Related topics

Related topics

3 relations
eltrombopageltrombopag 25 MG Oral Tabletromiplostim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
  • L. Loffredo, F. Violi
  • Digestive and liver disease : official journal of…
  • 2019
    • Corpus ID: 49613989
BACKGROUND Treatment of thrombocytopenia with thrombopoietin receptor agonists (TPORAs) seems to be associated with portal vein… Expand
Is this relevant?
Review
2016
Review
2016
Advances in Diagnosis and Treatments for Immune Thrombocytopenia
  • S. Nomura
  • Clinical medicine insights. Blood disorders
  • 2016
    • Corpus ID: 14735203
Immune thrombocytopenia (ITP) is an acquired hemorrhagic condition characterized by the accelerated clearance of platelets caused… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2016
2016
Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines
Very few data exist on the management of adult patients diagnosed with primary immune thrombocytopenia (ITP). The objectives of… Expand
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
2016
2016
Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand
Background: Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the… Expand
  • table 3
  • table 1
  • table 2
  • figure 1
  • table 4
Is this relevant?
2015
2015
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014
Background: The aim of this study was to evaluate the treatment reality for outpatients with immune thrombocytopenia (ITP… Expand
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
BACKGROUND Thrombopoietin receptor agonists (TRAs) are effective treatments for immune thrombocytopenia (ITP). However… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials
Thrombopoietin receptor agonists (TPOra) are the only treatments for immune thrombocytopenia (ITP) for which evidence of efficacy… Expand
Is this relevant?
2013
2013
Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities
Thrombopoietin receptor agonists (TRAs) offer new opportunities for the treatment of chronic immune thrombocytopenia (ITP… Expand
Is this relevant?
2012
2012
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
Immunosuppressive agents are the standard therapeutic approach for immune thrombocy-topenia (ITP). Their prolonged use may… Expand
  • figure 1
Is this relevant?
2011
2011
Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists
Aim: Thrombopoietin receptor agonists (Tpo increase platelet counts in the majority of chronic autoimmune thrombocytopenia… Expand
  • table 1
  • table 2
  • figure 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE